Report - Office of Clinical Pharmacology Review · pediatric indication, treatment of the heterozygous familial hypercholesterolemia (HeFH) in children ≥ 8 years to ≤ 16 years of age.

Select PornographicDefamatoryIllegal/UnlawfulSpamOther Terms Of Service ViolationFile a copyright complaint

Please pass captcha verification before submit form